InMode (INMD) to Release Earnings on Thursday

InMode (NASDAQ:INMD) is scheduled to release its earnings data before the market opens on Thursday, August 1st. Analysts expect InMode to post earnings of $0.30 per share for the quarter. InMode has set its FY24 guidance at $2.01-2.05 EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

InMode (NASDAQ:INMD) last posted its quarterly earnings results on Thursday, May 2nd. The healthcare company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.09. The company had revenue of $80.28 million during the quarter, compared to the consensus estimate of $80.10 million. InMode had a net margin of 38.84% and a return on equity of 26.15%. On average, analysts expect InMode to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

InMode Price Performance

INMD opened at $17.89 on Wednesday. InMode has a 1-year low of $16.44 and a 1-year high of $44.41. The stock has a market cap of $1.50 billion, a P/E ratio of 8.48 and a beta of 2.18. The stock’s 50 day simple moving average is $18.11 and its 200 day simple moving average is $19.86.

Analyst Ratings Changes

Several analysts have weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Thursday, July 11th. Jefferies Financial Group cut shares of InMode from a “buy” rating to a “hold” rating and cut their target price for the stock from $21.00 to $19.00 in a research report on Tuesday, July 23rd. Barclays reduced their price target on shares of InMode from $33.00 to $29.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Finally, Canaccord Genuity Group dropped their price objective on shares of InMode from $21.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, July 12th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.40.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.